ShanXi C&Y Pharmaceutical Group Co., Ltd. reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was CNY 363.38 million compared to CNY 402.85 million a year ago. Revenue was CNY 365.58 million compared to CNY 404.96 million a year ago.

Net loss was CNY 24.12 million compared to CNY 22.83 million a year ago. Basic loss per share from continuing operations was CNY 0.0998 compared to CNY 0.0982 a year ago. Diluted loss per share from continuing operations was CNY 0.0998 compared to CNY 0.0982 a year ago.